← Back to Portfolio

IFM Therapeutics

IFM Therapeutics was founded in 2015 to transform the treatment of cancer and inflammatory disease by developing drugs that target the innate immune system. In September 2017 the company was acquired for its oncology programmes by Bristol-Myers Squibb, in return for $300 million upfront and future milestone payments that could exceed $2 billion. At the same time, the company’s inflammation programmes were spun out into a new entity that retains the name IFM Therapeutics.

Location Boston, Massachusetts
CEO Gary Glick
Partner Vincent Miles
Website www.ifmthera.com